Poly(ADP-ribosyl)ation, catalysed by a family of poly (ADP-ribose) polymerases (PARPs), plays an important role in a large variety of physiological processes, including cell proliferation, but its role in cell cycle progression is not yet completely defined. As reported here, the examination of early times following serum stimulation of quiescent fibroblasts suggests that poly(ADP-ribosyl) ation is necessary for the transition from the G0 phase to the G1 phase. We show that PARP activity is involved in this step through the regulation of immediate-early response genes, such as c-Fos and c-Myc. This is supported by the finding that exogenous Myc expression substantially restores cell cycle reactivation in the absence of polymer synthesis. Furthermore, using RNA interference, we show that PARP-1 is the PARP family member playing the most prominent role in the upregulation of c-Fos and c-Myc during G0-G1 transition. We report that even in lectin-stimulated peripheral blood mononucleated cells, the inhibition of PARP activity interferes with the upregulation of immediate-early genes and delays the induction of proliferation, suggesting a general role for PARP-1 in linking growth factor signaling with cell cycle entry.
Introduction
Poly(ADP-ribosyl)ation is a rapid and transient posttranslational modification of nuclear proteins involving the transfer of homopolymeric (linear or branched) chains of ADP-ribose units (Schreiber et al., 2006) . The synthesis of poly(ADP-ribose) (PAR) is catalysed by PAR polymerases (PARPs), among which PARP-1 is the major anabolic enzyme in living cells (Shieh et al., 1998) . The targets of PARP-1 activity include PARP-1 itself, which is the primary target in vivo, core histones, the linker histone H1 and a variety of transcriptionrelated factors (D'Amours et al., 1999) . Through these modifications, PARP-1 participates in the regulation of chromatin structure (Rouleau et al., 2004) .
Activity of PARP-1 is stimulated by its binding to damaged DNA, acting as a DNA damage sensor, and is required for initiation of DNA repair (Schreiber et al., 2006) . Recently, additional mechanisms for PARP-1 activation, independent of DNA binding and in the absence of DNA damage, are emerging. A fast activation of PARP-1 is evoked by inositol 1,4,5,-trisphosphate-Ca(2 þ ) mobilization from the cell membrane of neuronal cells (Homburg et al., 2000) as well as by the interaction with structural viral proteins during Polyomavirus infection (Carbone et al., 2006) . Moreover, in rat astrocyte cell death, phosphorylation of PARP-1 by extracellular signal-regulated kinase1/2 (ERK1/2) triggers its activation (Kauppinem et al., 2006) . Furthermore, in a cell-free system, recombinant PARP-1 is activated by direct interaction with phosphorylated ERK-2 (Cohen- Armon et al., 2007) . These studies suggested a functional interaction between mitogen-activated protein kinase (MAPK) signaling and PARP-1 activation. It has been well established that the MAPK/ERK pathway plays an important role in the activation of the cell cycle machinery in mitogenstimulated cells (Treinies et al., 1999; Jones and Kazlauskas, 2001b) , thereby suggesting a possible role of PARP activity in linking growth factor signaling with cell cycle entry. To investigate this issue, we analysed the cell cycle activation of quiescent fibroblasts and peripheral blood mononucleated cells (PBMCs) . We demonstrate that PARP-1 activity is induced by mitogen stimulation and contributes to the G0-G1 transition through the induction of immediate-early genes (IEGs).
Results
Poly(ADP-ribosyl)ation is involved in mitogen-induced cell cycle re-entry At first, we studied whether PARP activity was modulated upon mitogen stimulation of quiescent fibroblasts, a useful model system to investigate the regulation of the initial steps of cell proliferation. Cells were growth-arrested by serum starvation and then stimulated by serum addition, as described in Materials and methods. The accumulation of PAR on cellular proteins, indicative of increased PARP activity, was measured at different times by western blot and immunofluorescence analyses. As shown in Figure 1a , serum addition induced a significant, transient increase of PAR levels, detectable within 30 min as evident diffuse signals in both mouse and human fibroblasts. Probing the same filters with a polyclonal antibody against PARP-1, the major poly(ADP-ribosyl)ating enzyme, we did not observe significant changes in the protein levels but, rather, an increase in its molecular weight, detectable as a smear, likely due to PARP-1 automodification activity (see below). Single-cell analysis by immunofluorescence staining, performed in mouse embryo fibroblasts, confirmed the occurrence of PARP activation in this cell type and also showed PAR accumulation in nearly all nuclei (Figure 1b) . These data indicate that increased PAR synthesis is a fast and synchronous response of quiescent fibroblasts to serum stimulation.
To investigate the importance of PARP activation in cell cycle re-entry, we analysed the effects of a potent competitive inhibitor of PARP activity, N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride (PJ-34) (Jagtap and Szabo, 2005) , on the ability of mitogen-stimulated cells to resume proliferation. Quiescent fibroblasts were stimulated with serum in the presence of different concentrations of the drug and the cell cycle profiles were determined at different times, up to 20 h, by flow cytometry. Analyses performed in both mouse and human fibroblasts revealed striking differences between control and PJ-34-treated cells after their release from quiescence. For a more direct comparison, we have reported the main values of the kinetics of S-phase entry (Figure 2 ). Control cells began to enter S phase 14-16 h after serum addition, and reached the highest value at 18-20 h. In contrast, treated cells showed a dosedependent perturbation of the kinetics of S-phase entry. In fact, although treatment with 3 mM PJ-34 allowed cells to correctly progress into the S phase, increasingly higher concentrations caused effects ranging from a delay to a complete blockade of S-phase entry. We observed that the PJ-34 concentration required to block Poly(ADP-ribosyl)ation in the G0 exit M Carbone et al cell cycle re-entry for NIH 3T3 mouse fibroblasts (60 mM) was higher than that required for human fibroblasts (30 mM). This difference probably reflects the higher PARP activity induced during the early phase of cell cycle re-activation in NIH 3T3 cells (Figure 1 ). Cell death, evaluated by trypan blue staining, did not exceed 0.1% in all samples, indicating that PJ-34 does not exert a significant cytotoxic effect, even at the highest concentration used. Moreover, a 20 h treatment with PJ-34 did not affect the cell cycle distribution of asynchronously proliferating cells, consistent with the low level of PAR synthesis detected in this condition (data not shown). These results extend previous findings that PARP activity can be induced by extracellular stimuli and suggest a functional link between mitogenic stimulation, PARP activation and release from quiescence. PARP activity regulates early response genes in serum-stimulated fibroblasts The induction of cell cycle re-entry by serum stimulation involves the activation of multiple signaling pathways, primarily MAPK/ERK and PI3K/AKT, which finally bring about complex changes in gene expression (Marshall, 1999; Sears and Nevins, 2002) . Upregulation of the IEGs, such as c-Myc and c-Fos, represents the first major program activated following exposure to mitogenic stimuli and marks the G0-G1 transition (Almendral et al., 1988; Bravo, 1990) .
We first wanted to exclude that PJ-34 treatment was interfering with an upstream step of mitogenic signaling. As shown in Supplementary Figure S1 , the inhibition of PARP activity in concomitance with serum stimulation did not prevent the phosphorylation, indicative of their activation, of ERK1/2 or AKT. Moreover, at least ERK1/ 2 underwent correct nuclear localization (data not shown).
To investigate the possible involvement of PARP activity in the upregulation of IEGs, we analysed their expression when serum stimulation was associated with PARP inhibition. Western blot analysis reported in Figure 3a and in Supplementary Figure S2 showed that treatment with PJ-34 caused a dose-dependent inhibition of PARP activity, as inferred both by the PAR levels and by the extent of PARP-1 modification. In particular, the lowest PJ-34 concentration, 3 mM, did not affect poly(ADP-ribosyl)ation, which, in contrast, was significantly reduced in the presence of 10 mM PJ-34 and decreased below the level of unstimulated cells in the presence of 30 mM PJ-34. As shown in the same figure, in parallel with the inhibition of PARP activity, PJ-34 caused a dose-dependent reduction of c-Myc and c-Fos protein levels re-emphasizing the dose-dependent interference with cell cycle reactivation described above. Extending the analysis to other IEGs and to later times ( Figure 3b ) we observed that PJ-34 also prevented the timely upregulation of JunB and Egr-1, similar to what it did for c-Myc and c-Fos. The delayed expression of IEGs (occurring between 80 min and 2 h) is accompanied by the failure of accumulating, within 5 h, cyclin D3, a downstream target of IEGs' activity and a marker for progression through the G1 phase. The observation that the inhibition of PAR synthesis did not influence the protein levels of the cyclin-dependent kinase inhibitor p27 excludes its contribution in preventing cell cycle progression. These results indicate that poly(ADPribosyl)ation is required for the proper and temporally coordinate induction of IEGs in a very early phase of exit from quiescence, playing a role upstream of their protein accumulation. Next, we investigated whether the expression of IEGs was affected at the RNA level. Total RNA was extracted from NIH 3T3 fibroblasts stimulated in the presence or absence of the PARP inhibitor. c-fos and c-myc RNA levels were measured over time by northern blot analysis. As shown in Figure 3c and Supplementary Figure S3 , PJ-34-treated cells exhibited a drastic reduction in c-fos and c-myc mRNA levels, when compared with untreated cells. Although other IEGs were not examined by this assay, on the basis of western blot analysis, we can infer that their mRNA levels are similarly compromised when poly(ADP-ribosyl)ation is abolished. Thus, the induction of PARP activity may be required for G0 exit by aiding the upregulation of IEGs at the RNA level. To follow the waves of expression of immediate-early genes after serum restoration, samples were collected every 20 min up to the second hour and at the third and fifth hour post serum addition (p.s.a.). Total cell extracts were used for western blot analysis with the listed antibodies. (c) Northern blot analysis was performed on total RNA extracted from quiescent and serumstimulated fibroblasts in the presence of 30 mM PJ-34, to reveal c-fos and c-myc mRNA levels. Ethidium bromide staining was reported to visualize the equal loading of the lanes. The statistical evaluation of the band intensities is reported in Supplementary Figure S3 . hrs.p.s.a., hours post serum addition; min.p.s.a., minutes post serum addition; PAR, poly(ADP-ribose); PARP-1, PAR polymerase-1; a-Tub, a-tubulin.
Poly(ADP-ribosyl)ation in the G0 exit M Carbone et al PARP activity regulates c-Myc and c-Fos expression in phytohemagglutinin-stimulated PBMCs As many early events induced by mitogen stimulation are shared by different cell types, we studied whether PARP activity plays a general role in other cell systems undergoing G0-G1 transition. Human PBMCs have been extensively employed for investigating the activation of resting T lymphocytes, a physiologically relevant system of quiescence. Interestingly, it has been recently reported that PARP activity is rapidly induced upon T-cell activation, in the absence of DNA damage (Valdor et al., 2008) , and that poly(ADP-ribosyl)ation regulates NFAT-dependent cytokine expression (Olabisi et al., 2008) . In light of our above results, we asked whether, in this cell system, PARP activity is also involved in the upregulation of IEGs, an even earlier event than the induction of interleukin-2 (Reed et al., 1986) . To this end we determined the effects of PJ-34 on c-Myc and c-Fos expression upon stimulation of PBMCs with the mitogenic lectin phytohemagglutinin (PHA). Freshly isolated human PBMCs were incubated with PHA in the presence or absence of PJ-34, for 72 h. Samples were collected at the indicated times, up to 2 h, for western blot analysis and, up to 72 h, for cytofluorimetric determination of cell cycle entry. As shown in Figure 4a and in Supplementary Figure S4 , the upregulation of c-Myc and c-Fos appeared significantly inhibited by PJ-34 early post-stimulation. As observed in fibroblasts, a recovery of their expression was detected later. Moreover, here again the delayed upregulation of IEGs was associated with a delayed kinetics of S-phase entry ( Figure 4b ). These data suggest that PARP activation can play a general role in the pathway regulating the proper induction of IEGs upon mitogen stimulation of resting cells.
Exogenous c-Myc complements PARP inhibition
To confirm that failure to induce IEGs was the main cause of the inability to re-enter cell cycle in the absence of PAR, we analysed the effects of restoring the expression of c-Myc, the critical role of which in the emergence from quiescence is supported by previous observations that its ectopic expression is capable to drive them from the G0 phase to the S phase (Eilers et al., 1991) . To this end, we used rat fibroblast cells stably expressing MycER, a fusion protein whose nuclear activation is regulated by estrogen addition (Littlewood et al., 1995) . We checked for the timing of cell cycle re-entry in the presence or absence of PJ-34. MycER and parental Rat2 control cells were stimulated and analysed by flow cytometry, as described above, and the results are shown in Figure 5 . Similar to the other cell lines, the inhibition of polymer synthesis prevented S-phase entry after serum stimulation. In contrast, the nuclear activation of exogenous Myc, induced by the estrogen (4-hydroxytamoxifen), was capable to overcome, to a significant extent, the block imposed by the PARP inhibitor. The residual inhibition, inferred by the slower kinetics of S-phase entry with respect to control cells, is likely due to the interference of PJ-34 with the expression of the other IEGs.
PARP-1 is required for the early response As mentioned above, PARP-1 is the most abundant PARP family member and is responsible for the synthesis of about 90% of the polymers present in the nucleus after DNA damage (D'Amours et al., 1999) . To assess its contribution in the pathway leading to cell cycle re-entry, we first determined the occurrence of PARP-1 automodification. To this end, PARP-1 was specifically immunoprecipitated from quiescent and serum-stimulated fibroblasts and then subjected to western blot analysis for PAR accumulation. As shown in Figure 6a , PARP-1 becomes significantly poly(ADPribosyl)ated within 15 min after serum addition. The inhibitory effect of PJ-34 on the automodification reaction confirms that PARP-1 activation is prevented in the presence of the drug. Next, to directly verify the requirement of PARP-1 in the early response, we Poly(ADP-ribosyl)ation in the G0 exit M Carbone et al analysed the effects of its knockdown by using small interfering RNAs (siRNAs). Mouse fibroblasts were cultured in low serum for 36 h and then transfected with a pool of oligos designed to reduce PARP-1 expression. After 48 h, cells were serum stimulated and analysed for PAR accumulation and for the induction of IEGs. The western blot reported in Figure 6b and in Supplementary Figure S5 shows that the specific knockdown of PARP-1 results in a drastic reduction of PAR accumulation, particularly evident at 30 min, the time corresponding to the peak of polymer synthesis. This indicates that PARP-1 accounts for most of the PARP activity induced by serum stimulation. Importantly, the reduction of PARP-1 levels and activity was associated with a significant inhibition of c-Fos and c-Myc upregulation. This result was confirmed by delivering the single siRNAs in separate transfections (Supplementary Figure S6 ). These data strongly suggest that PARP-1 is the poly(ADP-ribosyl)ating enzyme playing the most prominent role in the early response and in the decision of the cells to exit G0.
Discussion
Accumulating evidence indicate that PARP activity plays a physiological role in regulating cell proliferation by exerting distinct functions in different cell cycle phases. Although the best established functions of PARPs during cell cycle concern the control of chromosome segregation at mitosis, other reports indicate the involvement of these enzymes, particularly of PARP-1, in regulating cell cycle progression to other phases. PARP-1 acts at the S phase, both by participating in a multiprotein DNA replication complex (SimbulanRosenthal et al., 1996) and by acting as a positive regulator of E2F1-mediated transcription and, hence, of S-phase gene expression (Simbulan-Rosenthal et al., 1999 . Moreover, previous evidence correlated increased PARP expression and activity with liver regeneration (Cesarone et al., 1990) , PBMC activation (Menegazzi et al., 1992) and thymocyte proliferation (Wein et al., 1993) , but the role of PARPs in cell cycle re-entry was not further investigated.
In this work, we have studied the specific role of PARP activity in the highly regulated process that allows resting cells to resume proliferation, defining a novel function of poly(ADP-ribosyl)ation in cell cycle regulation.
We show that increased poly(ADP-ribosyl)ation, mainly involving the activation of PARP-1, is transiently detectable within 15 min after serum stimulation of quiescent fibroblasts. The observation that the rise of PARP-1 activity occurs without any change in protein abundance indicates that serum stimulation increases the catalytic activity of the pre-existing enzyme. This does not exclude that PARP activity may also be regulated, at later times of cell cycle reactivation, by transcriptional or translational mechanisms, as observed, for example, during the induction of thymocyte proliferation (Wein et al., 1993) . This observation extends previous findings that PARP-1 can be activated by extracellular stimuli, such as membrane depolarization and nerve growth factor in neuronal cells or angiotensin II in cardiomyocytes (Homburg et al., 2000; Cohen-Armon et al., 2007) . In agreement with the involvement of the ERK cascade in activating PARP-1 in these cell systems (Cohen-Armon et al., 2007), we found that a MEK inhibitor prevents PARP activation in serum-stimulated fibroblasts as well (data not shown). All these data suggest that the induction of PARP-1 activity, downstream of the ERK signaling, is a common response of different cell types to a variety of extracellular signals.
The functional importance of the prompt PARP activation in quiescent cells stimulated with serum was Poly(ADP-ribosyl)ation in the G0 exit M Carbone et al first suggested by the observation that PARP inhibitors interfere with the ability of these cells to re-enter cell cycle. In this regard, it is important to bear in mind that the use of competitive PARP inhibitors, such as PJ-34, has facilitated the dissection of many cellular functions of PARPs, and has been recently shown to provide therapeutic benefit in vivo in several dysfunctions involving poly(ADP-ribosyl)ation (Jagtap and Szabo, 2005) . Importantly, PJ-34 treatment causes a dosedependent interference with cell cycle reactivation, which correlates with a dose-dependent inhibition of PARP activity. In this regard, we found that full arrest of the poly(ADP-ribosyl)ation reaction requires PJ-34 concentrations (30-60 mM) higher than those usually applied to inhibit PARP activity after DNA damage (1-5 mM) (Jagtap et al., 2002) . The need of such concentrations could be explained by the extent of PARP activation induced by serum stimulation, which is comparably strong but more sustained with respect to that induced by genotoxic stimuli. Analysis of the early phases of the response to serum stimulation revealed that PARP-1 activation correlates with and is required for the timely upregulation of IEGs, such as c-Myc, c-Fos, Jun-B and Egr1. Significantly, although the induction of IEGs is recovered at later times, their delayed expression does not allow cells to correctly enter the S phase.
Our finding that PARP activity is required in a very early step of G0 exit does not exclude additional roles in other steps of the cell cycle, such as in the transition to the S phase. It has been suggested that the G0-S transition is composed of two growth-factor-dependent segments (Jones and Kazlauskas, 2001a) . According to this model, the first exposure involves the MAPK pathway and drives cells out of quiescence and through an early G1 (G1E). As cells complete G1E, they need a second exposure to growth factor to continue into late G1 (G1L), and the transition from G1E to G1L occurs at near 8 h. This second step involves the pRb/E2F pathway. c-Myc protein levels increase early (after 60 min) as well as later, suggesting that c-Myc also contributes to the events that drive cells through G1L (Jones and Kazlauskas, 2001a, b) . In this regard, Simbulan-Rosenthal et al. (1996) reported that PARP depletion by antisense RNA expression prevented S-phase entry of (differentiating) pre-adipocytes. Moreover, the same authors suggested that PARP-1, in addition to playing a direct role within the replicative apparatus, also modulates, through physical interaction, the activity of E2F1 in the regulation of several proteins involved in DNA synthesis, including the second wave of c-Myc (Simbulan-Rosenthal et al., 2003) . In this last study, however, the role of poly(ADP-ribosyl)ation was not addressed. Our results suggest that PARP activity is necessary to induce c-Myc expression at least in the G1E phase.
Significantly, we present evidence that PARP activation regulates IEGs in mitogen-stimulated PBMCs as well, thereby extending the relevance of this pathway to a more physiological system. Many past reports concerned the role of poly(ADP-ribosyl)ation in the rejoining of DNA strand breaks during lymphocyte activation (for example, Johnstone and Williams, 1982) . Some of these reports also examined the effects of Figure 6 Poly(ADP-ribose) polymerase-1 (PARP-1) is implicated in the early response. (a) Quiescent mouse fibroblasts were stimulated with serum in the presence or absence of 30 mM PJ-34, and collected at the indicated times. PARP-1 was immunoprecipitated using a specific polyclonal antibody and analysed by western blot (WB) using either a monoclonal antibody against the protein itself (right upper panel) or with an anti-PAR antibody (right lower panel). The lower intensity of the 116 kDa PARP-1 signal detectable in stimulated cells is consistent with the slower migration of the poly(ADP-ribosyl)ated form of the protein and with the reduced affinity of the monoclonal antibody for modified PARP-1 (Carbone et al., 2006) . Total lysates, loaded as a control, were probed with either polyclonal anti-PARP-1 (left upper panel) or anti-PAR (left lower panel) antibodies. (b) Quiescent mouse fibroblasts were transfected with siRNAs specific for PARP-1 or with the nonspecific siRNAs (siControl). Forty-eight hours later, the cells were stimulated with serum and collected at the indicated times. Cell extracts were then analysed by WB using the indicated antibodies. The statistical evaluation of the band intensities is reported in Supplementary Figure S5 . min.p.s.a., minutes post serum addition.
Poly(ADP-ribosyl)ation in the G0 exit M Carbone et al PARP inhibition on the induction of lymphocyte proliferation, but the results obtained were contrasting, probably due to differences in the experimental settings. In some cases, it was found that PARP inhibitors did not prevent lymphocyte entry into the cell cycle (for example, Marini et al., 1989) , whereas in others these drugs were reported to cause a marked inhibition of DNA synthesis and cell proliferation (for example, Ittel et al., 1983) . In our hands, PARP inhibition by PJ-34 did affect the progression of lectin-stimulated PBMCs to the S phase. This finding is consistent not only with the ability of the drug to interfere with c-Myc and c-Fos upregulation, but also with the recently described requirement of PARP activity for the transcription of interleukin-2 (Olabisi et al., 2008) , a key determinant in T-lymphocyte proliferation. Since the induction of IEGs represents an earlier and probably different step of lymphocyte activation (Reed et al., 1986) , we postulate that PARP activity may act in two temporally distinct phases in this system, like in fibroblasts.
As mentioned above, poly(ADP-ribosyl)ation is catalysed by a large family of proteins, with PARP-1 being the main isoform. Using RNA interference, we found that PARP-1 is responsible for most of the PAR accumulation induced by serum in quiescent cells. This is in line with the high levels of the enzyme automodification detected upon stimulation ( Figure 6a ) and with the previous observation that this family member is the target of ERK signaling (Cohen-Armon et al., 2007) . Most importantly, we found that PARP-1 is required for the upregulation of IEGs. This finding not only demonstrates the relevance of this family member in the early response to serum stimulation, but also allows us to exclude that the observed effects of PARP inhibitors can be ascribed to a nonspecific mechanism, other than inhibition of poly(ADP-ribosyl)ation.
Our observation that forced c-Myc expression counteracts, at least in part, the interference of PJ-34 with cell cycle re-entry strongly supports a causal link between inhibition of PARP activity, delayed upregulation of cMyc and delayed progression to S phase. Since PJ-34 also affects the expression of other IEGs, it makes sense to find that the restoration of c-Myc alone does not completely overcome the effect of PARP inhibition.
Regarding the mechanism by which PARP-1 induces the expression of IEGs, we have observed that c-Myc and c-Fos are induced at the RNA level. The accumulation of IEG RNAs is determined by complex mechanisms acting both transcriptionally and posttranscriptionally, as described for c-myc (Blanchard et al., 1985; Dean et al., 1986) . At the moment, we cannot establish in which type of mechanism poly(ADPribosyl)ation is involved, but it is reasonable that PARP-1 activity participates in the transcriptional control of IEGs. PARP-1 functions both as a structural component of the chromatin and as a modulator of chromatin function, in part, through its ability to induce transient histone modifications and/or modifications of transcriptional regulators at the enhancer/promoter level (Kraus and Lis, 2003) . The observation that PARP inhibition, even when protracted for several hours, delays, but does not completely block, the expression of IEGs, suggests that PARP-1 acts by modulating chromatin structure. Our hypothesis is that poly(ADPribosyl)ation participates in the fast and coordinate regulation of IEGs by helping the de-repression of chromatin domains during the transition from quiescence to proliferation. More work will be required to analyse the kinetics of PARP-1 interaction with early response genes and the chromatin modification profiles associated with their regulatory regions in relation to PARP-1 binding and activity.
Materials and methods
Cell culture and flow cytometric analysis Mouse embryonic fibroblasts, mouse NIH 3T3, Rat2, Rat Myc-ER and human diploid FB 1329 fibroblasts were grown in DMEM (Dulbecco's modified Eagle's medium; Gibco-BRL, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Cambrex, Walkersville, MD, USA), 2 mM Lglutamine, 1% pen/strep solution (vol/vol). For serum stimulation experiments, cells were seeded at 9 Â 10 5 cells per 90 mm dish, grown for 48 h in DMEM containing 0.1% FBS and then stimulated by incubation in growth culture medium supplemented with 10% FBS. The activation of Myc-ER was induced by the addition of 4-hydroxytamoxifen (Sigma-Aldrich) at 1 mM at the time of serum stimulation.
When indicated, PJ-34 (Sigma-Aldrich S.r.l., Milan, Italy), previously diluted in aqueous solution, was added. At the indicated times, triplicate plates of fibroblasts were trypsinized and counted. A total of 5 Â 10 5 cells were incubated with propidium iodide (Sigma-Aldrich) for 30 min in the dark. Cell cycle profiles of stained cells were obtained by flow cytometric analysis with FACS Calibur (BD Bioscience Pharmingen, San Diego, CA, USA).
Human PBMCs were cultured at 1.6 Â 10 6 cells/ml in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 1% pen/strep solution (vol/vol). PBMCs were stimulated with PHA-P (Sigma-Aldrich) at 5 mg/ml and, when indicated, PJ-34 was added. At the indicated times, 5 Â 10 6 PBMCs were recovered from cultures, washed and treated for western blot or flow cytometric analyses.
Western blot and immunofluorescence analyses
Cells were lysed in ice-cold RIPA buffer with protease inhibitors. Proteins were resolved by electrophoresis in 8% SDS-polyacrylamide gel and transferred to nitrocellulose membranes by electroblotting.
Membranes were blocked in 1% non-fat dry milk in phosphate-buffered saline containing 0.05% Tween 20 for 1 h at room temperature, and incubated with primary antibody overnight at 4 1C, then membranes were washed three times and incubated in a 1:10 000 or 1:20 000 dilution peroxidaseconjugated anti-mouse or anti-rabbit antibody, respectively (Bio-Rad, Hercules, CA, USA). Proteins were detected using the ECL chemiluminescence system (Pierce, Rockford, IL, USA). The following primary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA): c-Myc N-262 (sc-764), c-Fos 4 (sc-52), JunB 210 (sc-73), Egr-1 C-19 (sc-189), PARP-1 H-250 (sc-7150), cyclin D3 C-16 (sc-182), p27 C-19 (sc-528) and a-tubulin TU-02 (sc-8035). The anti-PAR (H-10) was purchased from Alexis (San Diego, CA, USA) and Trevigen (Gaithersburg, MD, USA). The monoclonal anti-PARP-1 (C2-10) was purchased from Alexis. The anti b-actin (A-3854) was purchased from Sigma-Aldrich. For the immunofluorescence analysis, cells were fixed in 50% methanol/50% acetone and stained with PAR antibody and DAPI (Sigma-Aldrich) to detect total nuclei. Fixed cells were analysed on Nikon Microphot FXA (Nikon, Tokyo, Japan) equipped with a Â 20 objective.
Northern blot RNA was extracted from NIH 3T3 cells after serum stimulation and prepared using the Nucleobond (MN, Du¨ren, Germany) extraction kit according to the manufacturer's instructions. For each sample, 10 mg of total RNA was separated by electrophoresis in a denaturing gel and transferred to a nitrocellulose membrane. Membranes were hybridized with 32 P-labeled probes. The probes for northern blot analysis of c-myc and c-fos were obtained by PCR amplification using the respective cDNAs from serum-stimulated cells as templates. As the regulation of IEG transcription is very complex, we designed probes that overlapped the junctions between coding exons to analyse mature mRNA. For detection of c-myc mRNA, the probe overlapped the 3 0 and 5 0 junctions of the second and the third exons, respectively. The oligonucleotides we used were as follows: c-myc forward, 5 0 -AAGCTGGTCTCGGAGAAGCTG-3 0 ; c-myc reverse, 5 0 -GGTTTGCCTCTTCTCCACAGA-3 0 . For detection of c-fos mature mRNA, we designed a probe that overlapped the 3 0 and 5 0 junctions of the first and the third exons, respectively. The oligonucleotides we used were as follows: c-fos forward, 5 0 -CGCAGAGCATCGGCAGAAGG-3 0 ; c-fos reverse, 5 0 -TGAGAAGGGGCAGGGTGAAGG-3 0 . The PCR products were purified by agarose gel extraction and used as templates for random priming labeling.
PARP-1 immunoprecipitation
A total of 3 Â 10 6 cells seeded in 10 mm dish were collected at the indicated times with RIPA buffer. For 1 ml of cellular lysate, 4 ml of primary antibody against PARP-1 from Alexis (210-302-R100) was used and samples were gently rocked overnight at 4 1C. Then proteinA-sepharose (Amersham, Buckinghamshire, UK) was added and samples were rocked for 3-5 h. ProteinA-sepharose was washed three times with RIPA buffer and the immunoprecipitated proteins were eluted with laemli 1 Â and collected for western blot analysis.
siRNA assay
Mouse embryonic fibroblast cells (1.8 Â 10 5 ) were grown for 36 h in DMEM containing 0.1% FBS, and then transfected with a mix containing 10 ml of lipofectamine 2000 reagent (Invitrogen Life Science Technologies, Carlsbad, CA, USA) plus 130 nM of SMART pool siRNA oligos from Dharmacon (Lafayette, CO, USA). After 48 h, cells were stimulated by incubation in DMEM with 10% FBS and lysed for western blot at the indicated times.
